Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies

BACKGROUND: CTLA-4 blockade with ipilimumab is Food and Drug Administration-approved for melanoma as a monotherapy and has been shown to modulate the circulating T-cell repertoire. We have previously reported clinical trials combining CTLA-4 blockade with granulocyte-macrophage colony-stimulating fa...

Descripción completa

Detalles Bibliográficos
Autores principales: Cham, Jason, Zhang, Li, Kwek, Serena, Paciorek, Alan, He, Tao, Fong, Grant, Oh, David Y, Fong, Lawrence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223469/
https://www.ncbi.nlm.nih.gov/pubmed/32376721
http://dx.doi.org/10.1136/jitc-2019-000368

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223469/
https://www.ncbi.nlm.nih.gov/pubmed/32376721
http://dx.doi.org/10.1136/jitc-2019-000368

Ejemplares similares